Mortality and Reinfarction among Patients Using Different Beta-Blockers for Secondary Prevention after a Myocardial Infarction
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Mortality and Reinfarction among Patients Using Different Beta-Blockers for Secondary Prevention after a Myocardial Infarction. / Andersen, Søren Skøtt; Hansen, Morten Lock; Gislason, Gunnar H; Folke, Fredrik; Schramm, Tina Ken; Fosbøl, Emil; Sørensen, Rikke; Rasmussen, Søren; Abildstrøm, Steen Z; Madsen, Mette; Køber, Lars; Torp-Pedersen, Christian; Andersen, Søren Skøtt; Hansen, Morten Lock; Gislason, Gunnar H; Folke, Fredrik; Schramm, Tina Ken; Fosbøl, Emil; Sørensen, Rikke; Rasmussen, Søren Poul Lind; Abildstrøm, Steen Z; Madsen, Mette; Køber, Lars; Torp-Pedersen, Christian.
I: Cardiology, Bind 112, Nr. 2, 2009, s. 144-150.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Mortality and Reinfarction among Patients Using Different Beta-Blockers for Secondary Prevention after a Myocardial Infarction
AU - Andersen, Søren Skøtt
AU - Hansen, Morten Lock
AU - Gislason, Gunnar H
AU - Folke, Fredrik
AU - Schramm, Tina Ken
AU - Fosbøl, Emil
AU - Sørensen, Rikke
AU - Rasmussen, Søren
AU - Abildstrøm, Steen Z
AU - Madsen, Mette
AU - Køber, Lars
AU - Torp-Pedersen, Christian
AU - Andersen, Søren Skøtt
AU - Hansen, Morten Lock
AU - Gislason, Gunnar H
AU - Folke, Fredrik
AU - Schramm, Tina Ken
AU - Fosbøl, Emil
AU - Sørensen, Rikke
AU - Rasmussen, Søren Poul Lind
AU - Abildstrøm, Steen Z
AU - Madsen, Mette
AU - Køber, Lars
AU - Torp-Pedersen, Christian
N1 - Keywords: Adrenergic beta-Antagonists; Aged; Atenolol; Bisoprolol; Female; Humans; Kaplan-Meiers Estimate; Male; Metoprolol; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Recurrence; Registries; Sotalol
PY - 2009
Y1 - 2009
N2 - Objectives: To study differences in the clinical efficacy of various brands of beta-blocker in secondary prevention after a myocardial infarction (MI). Methods: All patients hospitalized with a first MI between 1995 and 2002 who were still alive 30 days after discharge and had had at least one prescription for a beta-blocker filled were identified by individual-level linkage of nationwide registries of hospitalizations and drugs dispensed from pharmacies. A total of 32,259 MI patients were included in the study. Multivariable Cox proportional hazard models were used to analyze the risks of death and recurrent MI related to treatment with different beta-blockers. Results: The risks for death and recurrent MI were similar in patients using different beta-blockers, except that mortality from all causes among patients with a prescription for sotalol was higher. Subgroup analyses of high-risk patients with diabetes or congestive heart failure and of patients using comparable dosages of beta-blockers did not show effects on the risk of death or recurrent MI. Conclusion: Except for sotalol, the different types of beta-blocker had similar clinical efficacy in reducing mortality and the recurrence of MI. The equivalent efficacy remained when high-risk patients were analyzed separately Udgivelsesdato: 2008/7/9
AB - Objectives: To study differences in the clinical efficacy of various brands of beta-blocker in secondary prevention after a myocardial infarction (MI). Methods: All patients hospitalized with a first MI between 1995 and 2002 who were still alive 30 days after discharge and had had at least one prescription for a beta-blocker filled were identified by individual-level linkage of nationwide registries of hospitalizations and drugs dispensed from pharmacies. A total of 32,259 MI patients were included in the study. Multivariable Cox proportional hazard models were used to analyze the risks of death and recurrent MI related to treatment with different beta-blockers. Results: The risks for death and recurrent MI were similar in patients using different beta-blockers, except that mortality from all causes among patients with a prescription for sotalol was higher. Subgroup analyses of high-risk patients with diabetes or congestive heart failure and of patients using comparable dosages of beta-blockers did not show effects on the risk of death or recurrent MI. Conclusion: Except for sotalol, the different types of beta-blocker had similar clinical efficacy in reducing mortality and the recurrence of MI. The equivalent efficacy remained when high-risk patients were analyzed separately Udgivelsesdato: 2008/7/9
U2 - 10.1159/000143389
DO - 10.1159/000143389
M3 - Journal article
C2 - 18612201
VL - 112
SP - 144
EP - 150
JO - Cardiologia
JF - Cardiologia
SN - 0008-6312
IS - 2
ER -
ID: 10166128